Nonalcoholic Steatohepatitis Therapeutics Market
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
differentiate NASH from other causes of liver disease that have<br />
a similar appearance.<br />
<strong>Nonalcoholic</strong> fatty liver disease (NAFLD) is a disorder<br />
categorized by excess fat in the liver of people who drink little<br />
to no alcohol. No direct cause has yet been identified, however<br />
obesity and insulin resistance are believed to have major roles.<br />
Most often, NAFLD goes relatively undetected, as a liver can<br />
remain fatty without obstructing its function. Though, NAFLD<br />
can progress into a far more severe condition known as<br />
nonalcoholic steatohepatitis (NASH), a disease characterized by<br />
inflammation and irreversible cell death.<br />
Browse Full Research Report on <strong>Nonalcoholic</strong><br />
<strong>Steatohepatitis</strong> <strong>Therapeutics</strong> <strong>Market</strong>:<br />
http://www.transparencymarketresearch.com/nonalcoholicsteatohepatitis-market.html<br />
NASH is a disease that advances over time. Over a period of ten<br />
years up to 20% of patients with NASH develop cirrhosis of the<br />
liver, and 10% die from the disease. At present, NASH is one of<br />
the leading causes of liver transplants in the U.S., with a<br />
considerable proportion of the general population currently<br />
suffering from the disease.<br />
NAFLD and NASH are both closely related to diabetes and<br />
obesity, and together are now considered as the leading cause of
Change language